Tissue-repair research
TB-500: Research, Human Evidence and Safety
Peptide fragment discussed in research; no FDA-approved human treatment indication is identified here.
Overview
TB-500 is a common name associated with a thymosin beta-4 fragment. This listing does not claim that it heals injuries or is an established human treatment.
How it works
Mechanistic descriptions in laboratory research are not proof of clinical benefit or safety in people.
Uses described in the source
FDA states it has not identified human exposure data for drug products containing this fragment and lacks important safety information. Clinical effectiveness for human use is not established.
Evidence
Insufficient human safety and efficacy evidence
Regulatory status
No FDA-approved human indication is identified here. FDA has listed this fragment among bulk substances that may present significant safety risks in compounding; this does not determine Colombian status.
Safety
FDA notes possible immunogenicity, aggregation and peptide-impurity risks, and says human exposure data for drug products containing the fragment have not been identified. Safety and effectiveness for human treatment are not established.
YouMedicine availability
Investigational / educational only. No treatment availability is claimed.
Sources
Do not use research summaries to self-treat or to infer that a product is suitable, approved, or legally available.